Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Authorized" Generics Violate Predatory Pricing Laws, Mylan Lawsuit Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan alleges P&G and Watson violated Robinson-Patman and Sherman antitrust laws by selling an "authorized" generic of Macrobid below cost with the intent to monopolize the market. The lawsuit is aimed at preventing authorized generics during Mylan's 180-day exclusivity period for Norvasc, Levaquin and Ditropan XL.

You may also be interested in...



Mylan Loses Challenge To “Authorized” Generics In W.Va. Court

Federal judge says 180-day exclusivity period was not intended to prohibit competition from NDA holder.

Mylan Loses Challenge To “Authorized” Generics In W.Va. Court

Federal judge says 180-day exclusivity period was not intended to prohibit competition from NDA holder.

Mylan Dismisses “Authorized” Generic Antitrust Claims In W.Va. Lawsuit

Company instead is pressing on with antitrust claims filed in a March 2004 lawsuit in San Francisco state court stemming from Procter & Gamble and Watson’s “authorized” generic agreement for Macrobid. The West Virginia litigation would have been duplicative of the California claims, Mylan says.

Related Content

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel